Literature DB >> 93138

Radioimmunological determination of serum 3 beta-hydroxy-5-cholenoic acid in normal subjects and patients with liver disease.

E I Minder, G Karlaganis, G Paumgartner.   

Abstract

A radioimmunoassay for the determination of 3 beta-hydroxy-5-cholenoic acid in human serum has been developed, using 3 beta-hydroxy-5-cholenoyl-thyroglobulin as immunogen and 3 beta-hydroxy-5-cholenoylglycyl-125I histamine as radioactive ligand. The association constant was 6.3 X 10(8) l/mol. Cross reactivity with other bile acids of human serum was not detectable, but was 5.6% with cholesterol. Serum sample preparation included extraction of 3 beta-hydroxy-5-cholenoic acid from serum, solvolysis of sulfates, hydrolysis of conjugates, and separation from cholesterol by thin-layer chromatography. Serum concentrations of 3 beta-hydroxy-5-cholenoic acid were 0.23 +/- SD 0.12 mumol/l and 0.21 +/- SD 0.09 mumol/l in healthy males and females, respectively. In patients with primary biliary cirrhosis the serum concentration of 3 beta-hydroxy-5-cholenoic acid and the quotient 3 beta-hydroxy-5-cholenoic acid over total 3 alpha-hydroxy-bile acids (measured enzymatically) were significantly higher (P less than 0.02) than in patients with chronic active hepatitis or alcoholic cirrhosis. Analysis of 17 sera with elevated concentration of 3 beta-hydroxy-5-cholenoic acid by radioimmunoassay and capillary gas-liquid chromatography showed a close correlation (r = 0.91, slope = 0.97) between the results of the two methods.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 93138

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  4 in total

1.  Parenteral lipids shape gut bile acid pools and microbiota profiles in the prevention of cholestasis in preterm pigs.

Authors:  Lee Call; Tiffany Molina; Barbara Stoll; Greg Guthrie; Shaji Chacko; Jogchum Plat; Jason Robinson; Sen Lin; Caitlin Vonderohe; Mahmoud Mohammad; Dennis Kunichoff; Stephanie Cruz; Patricio Lau; Muralidhar Premkumar; Jon Nielsen; Zhengfeng Fang; Oluyinka Olutoye; Thomas Thymann; Robert Britton; Per Sangild; Douglas Burrin
Journal:  J Lipid Res       Date:  2020-04-29       Impact factor: 5.922

2.  Serum Metabolomics and Incidence of Atrial Fibrillation (from the Atherosclerosis Risk in Communities Study).

Authors:  Alvaro Alonso; Bing Yu; Yan V Sun; Lin Y Chen; Laura R Loehr; Wesley T O'Neal; Elsayed Z Soliman; Eric Boerwinkle
Journal:  Am J Cardiol       Date:  2019-03-18       Impact factor: 2.778

3.  Comprehensive Metabolomics Study in Children With Graves' Disease.

Authors:  Qin Xia; Weifeng Qian; Linqi Chen; Xiuli Chen; Rongrong Xie; Dandan Zhang; Haiying Wu; Hui Sun; Fengyun Wang; Jingjing Liu; Ting Chen
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-16       Impact factor: 5.555

4.  Metabolomics and Incidence of Atrial Fibrillation in African Americans: The Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  Alvaro Alonso; Bing Yu; Waqas T Qureshi; Morgan E Grams; Elizabeth Selvin; Elsayed Z Soliman; Laura R Loehr; Lin Y Chen; Sunil K Agarwal; Danny Alexander; Eric Boerwinkle
Journal:  PLoS One       Date:  2015-11-06       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.